hiHep bioartificial liver therapy

Phase 1Biologic

SSir Run Run Shaw Hospital

hiHep bioartificial liver therapy is one of 3 biologic programs targeting Hepatectomy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatectomyRecruiting

HepatectomyPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Hepatectomy

#DrugCompanyPhaseTrials

Medrol

Pfizer

Phase 3

1 2

hiHep bioartificial liver therapy

SSir Run Run Shaw Hospital

Phase 1

1 3

Dexmedetomedine

AAlRefaey Kandeel

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

Hepatectomy

NCT05035108

Clinical

Trials by Indication[1]

Hepatectomy1 trial

The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy

Recruiting·SSir Run Run Shaw Hospital·Phase 1·NCT05035108·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hiHep bioartificial liver therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hiHep bioartificial liver therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hiHep bioartificial liver therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sir Run Run Shaw Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSir Run Run Shaw Hospital

hiHep bioartificial liver therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Hepatectomy1 trial

References

Drug Info

Quick Facts

Related News